Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
10-1-2020 9:30 AM

Identification of the Signalosome and Signaling Pathway of the
Efferocytic Receptor MERTK
Tarannum Tasnim, The University of Western Ontario
Supervisor: Heit, Bryan, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Microbiology and Immunology
© Tarannum Tasnim 2020

Follow this and additional works at: https://ir.lib.uwo.ca/etd

Recommended Citation
Tasnim, Tarannum, "Identification of the Signalosome and Signaling Pathway of the Efferocytic Receptor
MERTK" (2020). Electronic Thesis and Dissertation Repository. 7387.
https://ir.lib.uwo.ca/etd/7387

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
MER Tyrosine Kinase (MERTK) is a receptor that mediates efferocytosis - the phagocytosis
of apoptotic cells. Efferocytosis is central to homeostasis through removing the ~150 billion
apoptotic cells generated each day in the human body. Defects in MERTK function have
been shown to contribute to both autoimmune diseases and chronic inflammatory diseases,
and MERTK is known to function as the predominant or sole efferocytic receptor in multiple
tissues. Despite its clinical importance, very little is understood of how MERTK functions
and how it signals. MERTK is known to bind to apoptotic cells via opsonins such as Gas6
and Protein S, with binding activating MERTK’s intrinsic kinase domain. This induces a
poorly characterized signaling pathway which is thought to coordinate with integrins to
mediate efferocytosis. Using immunoprecipitation and mass spectrometry we have identified
a large pre-formed MERTK signalosome on the cell surface containing MERTK, integrins
and a number of lipid and protein kinases. Ligation of this complex activates a number of
downstream signaling pathways required for efferocytosis, including the canonical
Src/Syk/PI3K phagocytic signaling pathway and non-canonical ILK and Erk-dependent
signaling pathways. Through ILK and FAK, MERTK signaling activates integrins, and
indeed, in macrophages MERTK-mediated efferocytosis requires α xβ2 integrins. Combined,
these data demonstrate that MERTK engages in efferocytosis cooperatively with integrins,
and mediates this cross-talk through engaging canonical integrin signaling pathways.

Keywords
MERTK, efferocytosis, integrin, atherosclerosis, autoimmunity, phagocytosis, apoptotic cells,
PI3K, ILK, FAK.
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Lay Abstract
Everyday our body replaces billions of cells. These cells need to be replaced due to damage
or aging. These cells are removed through a special form of cell death called apoptosis,
where the cells deliberately disassemble themselves into small “packages” that can be easily
removed. These packages are removed by specialized cells, including a type of immune cell
called “macrophages”. This removal process is called efferocytosis, and during efferocytosis
the macrophage will engulf and break down the dying cell. This process is very important
for the maintenance of our bodies, and without it our tissues accumulate dying cells and
begin to break down. MERTK is critical to efferocytosis – it is a receptor on macrophages
that allows them to detect the presence of dying cells. Defects in MERTK function leads to
several inflammatory and immune related diseases, including heart disease. However very
little is known about how MERTK functions, and how it allows macrophages to remove
dying cells. We have found that MERTK is assembled into large clusters along with multiple
other proteins. We have identified several of these MERTK-associated proteins and shown
that several of these proteins are required for macrophages to efferocytose dying cells. These
critical proteins include ILK and FAK, which allow MERTK to communicate with another
receptor known as αxβ2 integrin. MERTK cannot engage in efferocytosis without α xβ2
integrin, and we have shown that MERTK first identifies the dying cell, then activates α xβ2
integrin via ILK and FAK, with αxβ2 integrin then binding to the dying cell strongly enough
for the macrophage engulf the dying cell. Together, these experiments demonstrate how
MERTK mediates efferocytosis and demonstrates an important role of α xβ2 integrin in this
process. Using this information, it may be possible to develop better treatments for diseases
driven by defects in efferocytosis, including heart disease – the most common cause of death
in the world.
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Chapter 1

1

Introduction

1.1

Efferocytosis and Homeostasis

Efferocytosis is the phagocytic clearance of apoptotic cells (AC) and is necessary for
tissue homeostasis. The human body turns-over almost 150 billion cells through
apoptosis daily, with the bulk of these cells removed via efferocytosis 1,2. Effective
efferocytosis removes these dying cells, but any defect in efferocytosis leaves ACs
uncleared. Because ACs are no longer metabolically active, they cannot maintain their
membrane integrity, eventually leading uncleared ACs to lyse through secondary
necrosis. This necrosis releases autoantigens and pro-inflammatory cytokines that can
give rise to a number of disorders such as atherosclerosis, autoimmunity and
neurodegeneration and if the AC was infected, release of the pathogen 3–8.
While phagocytosis is mediated by various professional phagocytes including
polymorphonuclear leukocytes and immature dendritic cells, the bulk of efferocytosis is
performed either by macrophages, or in some tissues, non-professional phagocytes such
as epithelial cells. Cells that are undergoing apoptosis activate membrane scramblases
that transport the normally intracellular lipid phosphatidylserine (PtdSer) to the exofacial
side of the plasma membrane where it acts as an “eat-me signal” 9–11. Efferocytic
receptors on macrophages recognize and bind to PtdSer, either directly or through an
opsonin, to induce the engulfment of the AC by the efferocyte. Following engulfment,
the AC-containing vacuole – termed the ‘efferosome’ – receives degradative enzymes
through fusion with endosomes and lysosomes, leading to degradation of the AC by the
efferocyte12. Through this engulfment and degradation process, efferocytosis clears the
tissues of AC’s, thus maintaining homeostasis and avoiding the inflammation and
autoimmunity which can follow secondary necrosis.
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1.2

Overview of Apoptosis

Apoptosis is a distinct form of programmed cell death that contributes to homeostasis by
removing damaged or otherwise unneeded cells. Apoptosis can be triggered by either
intracellular stressors (intrinsic apoptosis) or activation of pro-apoptotic receptors by
external stimuli (extrinsic apoptosis)13. Both the intrinsic and extrinsic pathways activate
cysteine-aspartic proteases (caspases) that act as effectors of the apoptotic process 14–16.
Caspases are synthesized as inactive proenzyme forms called pro-caspases in which
their carboxy-terminal protease domain are inhibited by the amino-terminal prodomains. Cleavage of the pro-domains lead to the activation of caspases 14,17. Caspases
can be classified into two classes: initiator and effector caspases. Initiator caspases
(caspase-2, 8, 9, and 10) activate apoptosis through cleaving the pro-domains of effector
caspases. In contrast, effector caspases (caspase-3, 6, and 7) cleave cellular proteins
including actin and cyclin A, thus facilitating the disassembly of the AC18,19. The
intrinsic and extrinsic apoptosis pathways activate different initiator caspases, but both
pathways converge on caspase-3. Caspase-3 is an effector caspase which acts as the
master regulator of the disassembly process through activation of many apoptosis
effectors, for example, caspase-activated DNase, which causes degradation of
chromosomal DNA into nucleosomal units during apoptosis 20.
In addition to caspases, other effector proteins are involved in the degradation of other
cellular components, and for the packaging of apoptotic cellular materials into
membrane-derived blebs 20,21. Together these effector proteins produce the typical
morphological hallmarks of apoptosis such as nuclear fragmentation, disassembly of
subcellular organelles, re-distribution of plasma membrane lipids, and packaging of
cellular contents into small membrane blebs. Apoptotic blebs are blister like protrusions
of plasma membrane that are formed by actin-myosin contraction of the cortical
cytoskeleton. These blebs contain the degraded cytoplasmic materials, condensed
chromatin and organelles, and detach from the AC to form apoptotic bodies which can
then be efferocytosed22,23. These membrane blebs serve three functions: 1) they contain
intracellular materials to prevent their release into the surrounding tissue, thus
preventing inflammation and autoimmunity, 2) they package cellular materials into a
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particle sized for efficient uptake by phagocytes, and 3) they bear PtdSer on their
surface, demarcating them for removal12. These eat-me signals are recognized by
efferocytic receptors on cells such as macrophages, which then remove the AC. Heathy
cells are not targeted by these receptors, as flippases - transmembrane lipid transporter
proteins - maintain the asymmetrical distribution of PtdSer by flipping any PtdSer on
the exofacial leaflet to the cytosolic leaflet of the plasma membrane. During apoptosis,
signals from elevated calcium ions and activation of Caspase 3 and 7, activates
phospholipid scramblases while inactivating flippases, thus disrupting membrane
asymmetry and exposing PtdSer on the exofacial surface 10–12.

1.3 Overview of Efferocytosis
The ultimate goal of efferocytosis is to remove ACs while being anti-inflammatory and
non-immunogenic. Receptor recognition of “eat-me” signal initiates the engulfment of
the AC into an efferosome. The nascent efferosome fuses sequentially with early
endosomes, late endosomes, and finally lysosomes, thus delivering the hydrolytic
enzymes to the efferosome that create the degradative environment which breaks down
the AC24. Our lab has shown that the trafficking of this efferosome is different from
pathogen-containing phagosomes, in that it does not mature into an MHC II loading
compartment. Instead, efferosomes recruit Rab17 which mediates the transport of
degraded AC material to the recycling endosome. This prevents AC-derived antigens
from being presented on MHC II, thereby reducing the risk of autoimmunity, and may
also aid in the recovery of nutrients from the AC25,26. In addition, immediately after the
efferocytosis of an AC, the efferocytosing cell activates PPARγ, which supresses early
inflammatory responses and initiates the expression of anti-inflammatory cytokines
including IL-10 and TGF-ß27. Combined, these processes enable a phagocyte to remove
an AC in a manner which prevents inflammation and autoimmunity, while
simultaneously generating a cytokine profile which promotes tissue healing and
homeostasis.
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1.4 Efferocytic Receptors
ACs are recognized by a large range of efferocytic receptors. These receptors either
recognize eat-me signals directly, or via opsonins. While there are a large number of
efferocytic receptors, most of them belong to a smaller number of receptor families.
These include integrins such as αxβ2 and αvβ5, which recognize AC indirectly through
opsonin such as sCD93 and milk fat globule EGF factor 8 (MFG-E8) 28. Other
efferocytic receptors directly bind to PtdSer on ACs, including the T cell
immunoglobulin- and mucin-domain-containing molecule (TIM) family (TIM-1, TIM-3
and TIM-4) 29–33, as well as the G-protein coupled receptor Brain-specific Angiogenesis
Inhibitor-1 (BAI-1),34. A third major group of efferocytic receptors is the CD300 family
of proteins. While the CD300 family of receptors bind PtdSer directly, their role in
efferocytosis is not well defined. Indeed, while some CD300 members – e.g. CD300lb –
are pro-efferocytic, other members of this family may act as inhibitory receptors 35.
While there are a large number of efferocytic receptor families, one family appears to be
the predominant receptor used for efferocytosis in many tissues, including by immune
cells such as macrophages. These belong to the receptor tyrosine kinase (RTK’s) superfamily, based on the presence of a C-terminal tyrosine kinase domain. There are 58
RTKs in the human genome that are classified into 20 families 36, of which one family –
the TAM family – are efferocytic. This family is named after its constituent members:
Tyro, Axl, and MER tyrosine kinase (MERTK) 37, and they regulate a variety of cellular
functions including efferocytosis, platelet aggregation, and natural killer (NK) cell
differentiation. TAM receptors share a common structure: an extracellular domain
containing tandem immunoglobulin-related (Ig) and fibronectin-like domains, a helical
transmembrane domain, and a conserved intracellular kinase domain containing the
KW(I/L)A(I/L)ES consensus sequence. TAM receptors form homodimers which bind to
PtdSer indirectly through opsonins, with these opsonins bound by the two Ig domains
present at the N-terminus of the TAM receptor38–42 (Figure 1).
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1.5 TAM Receptor Opsonins
The TAM receptors share a common mechanism of AC recognition. Rather than binding
to ACs directly, they instead rely on the soluble opsonins Growth arrest-specific 6
(Gas6), Protein S (PROS)7, and potentially other proteins including Tubby, Tubby-Like
Protein 1, and Galectin-344–46.
Gas6 and protein S are both around 80 kDa, and share ~44% amino-acid identity 47.
These ligands contain a sex hormone-binding globulin (SHBG) domain at the carboxy
terminal end and a Gla domain at the amino terminal end, with these domains separated
by four epidermal growth factor (EGF)-related domains. The ~60 amino-acid Gla
domain, which is rich in glutamic acid residues are γ-carboxylated in a vitamin-Kdependent reaction. This γ-carboxylated Gla domain mediates Ca 2+-dependent binding
to negatively charged PtdSer on the surface of the AC, while the SHBG domain of the
opsonin binds to the immunoglobulin domains of the TAM receptors. Binding induces
tighter TAM dimerization, cross-activation of the tyrosine kinase domain, thus initiating
downstream signaling48–51 (Figure 1). This downstream signaling pathway is yet to be
fully elucidated but is known to induce activation of phosphatidylinositol 3-kinase
(PI3K) and extracellular signal-regulated kinase (ERK). PI3K has been shown to be
required for efferocytosis52,53, while the other pathways appear to regulate proliferation,
migration, differentiation, adhesion, and the inhibition of apoptosis 49,51,54. Some
receptor-specific signaling pathways are also activated. For example, TAM receptors
activates SOCS3, which inhibits inflammatory signaling and promotes an antiinflammatory response55,56.
It has been well established that Gas6 can bind and activate all three members of the
TAM receptor family. In contrast, protein S can bind and activate MERTK and Tyro3 57.
However, Gas6 is the sole opsonin for Axl and also has the strongest binding affinity for
Axl – indeed, Axl binds to Gas6 independently of PtdSer, although this interaction does
not appear to induce signaling58. Despite this higher affinity, MERTK is more
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Apoptotic cell
GLA domain
Gas6/Pros

EGF like domain
SHBG domain

Ig domain

TAM receptor

Efferocyte

FNIII domain

TK domain

Figure 1: Structure of TAM receptor and their ligands. TAM receptors are
composed of an extracellular domain, a transmembrane domain, and a conserved
intracellular kinase domain. The amino-terminal regions of the extracellular domain
contain two immunoglobulin-related domains followed by two fibronectin type III
repeats and their ligands, Gas6 and protein S contain a Gla domain at the amino
terminus which bind to the phospholipid phosphatidylserine expressed on the surface of
the AC, and an SHBG domain - which is separated from the Gla domain by four EGF
like repeats – that binds to the immunoglobulin (Ig) domains of the TAM receptors.
Opsonin binding induces dimerization, and activates the tyrosine kinase domain of the
TAM receptor43.
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readily activated when exposed to Gas6 in the presence of PtdSer58. While Gas6
appears to function only as an opsonin, Protein S has additional functions. Indeed,
Protein S is highly abundant, and is present at a concentration of ~300 nM in the serum
where it serves as an essential cofactor for activated protein C and inhibits blood
coagulation59. In comparison, Gas6 is present at a lower concentration, ranging from
0.02 to 0.2 nM, and does not have a known role in the coagulation system 60.

1.6 TAM Signaling
The signaling required for the uptake of large particulate objects – e.g. pathogens via
phagocytosis – is well established61. This requires the activation of Src-family kinases
(SFK), and the Rho-family GTPases Rac1 and CDC42, to induce the actin
reorganization required to engulf particulates. Larger particulates (>1 µm) require
amplification of this actin reorganization pathway via phosphatidylinositol-3-kinase
(PI3K) signaling24,62–66. As the TAM receptors are capable of inducing the uptake of
large ACs it is likely that they activate these pathways. However, only the activation of
the PI3K pathway has been previously demonstrated, with this activation occurring
through the same canonical pathway as PI3K activation downstream of phagocytic Fcγ
receptors24,67,68. Signaling is initiated by binding of opsonins that have formed multimers
on the surface of an AC62,69–71. This results in TAM receptor dimerization and induces
autophosphorylation at two sites, within the tyrosine kinase domain (TKD) and in the Cterminal tail. Kinase domain phosphorylation activates the kinase domain, allowing it to
phosphorylate downstream targets62 – most of which remain undefined. Phosphorylation
of the C-terminal tail forms a binding site for growth factor receptor-bound protein 2
(Grb2). Grb2 recruits the p85 subunit of PI3K, followed by the p110 kinase subunit
which phosphorylates phosphatidylinositol-4,5-bisphosphate ((PI(4,5)P2) to form
phosphatidylinositol-3,4,5-trisphosphate (PIP3)72,73. PIP3, via PH domains specific to
this lipid, initiate downstream phosphorylation of substrates such as Akt and mTOR.
PI3K/Akt signaling drives many downstream processes including proliferation, cell
survival and growth. This Akt signaling has an unclear role in the efferocytosis of
ACs74.
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TAM signaling also suppresses inflammatory responses through inhibiting inflammatory
cytokine signaling via the JAK/STAT pathway75,76. Janus kinases (Jaks) are
constitutively associated with cytokine receptors and are phosphorylated upon ligand
binding. Activated Jaks phosphorylate specific tyrosine residues on the cytoplasmic
domain of cytokine receptor and SH2 domains of STATs, which then dissociate from
the cytokine receptor, dimerize, and translocate to the nucleus to induce the expression
of pro-inflammatory genes. Active TAM receptors antagonize this pathway through
binding to and activating type-1 interferon receptors (IFNAR), which drives the
expression of the JAK/STAT inhibitors, Suppressor of Cytokine Signaling -1 & 3
(SOCS1 & SOCS3). SOCS1/3 then antagonize STAT activation, thereby inhibiting
cytokine signaling and limiting inflammation. Given that SOCS1/3 must be first
transcribed before they can mediate their effect downstream of TAM receptors, it is
unlikely that these proteins are directly involved in the engulfment of ACs, and rather,
the role of these proteins is most likely limited to events occurring hours after AC
engulfment77,78.

1.7 TAMs in Autoimmunity and Inflammation
Retinitis pigmentosa is an example of the importance of MERTK to tissue homeostasis.
This is a genetically heterogeneous inherited retinal dystrophy which mainly affects rod
photoreceptor cells and is characterized by progressive night blindness, constriction of
the visual field, and eventually complete blindness 79,80. More than 80 genes have been
implicated in non-syndromic cases of retinitis pigmentosa. MERTK is one of these
genes, with several mutations in MERTK associated with the pathogenesis of retinitis
pigmentosa. Importantly, MERTK is one of the only genes associated with retinitis
pigmentosa which causes disease in a monogenic fashion – i.e. mutations in MERTK are
sufficient to cause disease – while other genes associated with this disease typically
cause disease in a polygenic fashion81,82.
The function of MERTK was first discovered in the retinal pigment epithelium (RPE) of
the Royal College of Surgeons (RCS) rat. This is the first known animal with inherited
retinal degeneration. These rats develop progressive blindness due to a lack of MERTK
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expression by RPE cells83,84. Normally, RPE cells are phagocytic, serving the roles
played by macrophages in other tissues. In the retina these cells utilize MERTK to
recycle the photoreceptor (rods) outer segments. Rod cells are photosensitive, highly
segmented cells, comprised of sequential layers of photoreceptor outer segments stacked
on top of each other. New photosensitive segments are continually produced at the cell
base, causing the receptor segments to move further away from the cell base over time.
These segments are the light-detecting portion of the cell and become photodamaged
over time. The outermost, highly damaged segments are shed from the rod cell, at which
point they take on an AC-like phenotype by exposing PtdSer 85–87. Normally, retinal
pigment epithelium cells efferocytose these outer segments via MERTK, clearing the
retina of these debris84,88–91. In the RCS rat, inactivating mutations in MERTK prevent
this clearance, allowing photodamaged outer segment to accumulate, leading to
blindness due to the inflammation induced following secondary necrosis of these
uncleared outer segments. This same process occurs in patients bearing a number of
different mutations in MERTK, with these mutations driving the most acute form of
retinitis pigmentosa wherein patients experience more severe disease, earlier
manifestation, and quickly worsening macular atrophy, compared to disease driven by
other mutations 84,92–97.
Interestingly both TAM triple knockout (TKO) and MerTK-/- mice are born with a
normal retina, but go blind two months after birth due to extensive accumulation of the
photodamaged outer segment, a phenotype not observed in Tyro3 or Axl single
knockouts37,94. In humans, mutations in MERTK, but not TYRO3 or AXL, have also been
shown to lead to retinitis pigmentosa, highlighting the importance of MERTK compared
to other TAM receptors in the homeostasis of the eye 98.
Atherosclerosis is a chronic inflammatory disease triggered by the accumulation of
modified lipoproteins (moLDL) such as oxidized low-density lipoprotein (oxLDL) in the
subendothelial space99,100. These deposits are cleared by macrophages, but the cell stress
induced by these moLDLs often lead to the apoptotic death of the macrophage 100–102.
Normally, these would be cleared by other macrophages, but in ~50% of people this
efferocytic process fails, leading to the accumulation of apoptotic, cholesterol-laden
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macrophages beneath the vasculature of the heart103,104. As these cells necrose, they form
into atherosclerotic plaques – large masses of cellular debris and cell-free lipids. These
plaques are weak and prone to rupture, and if they rupture, the resulting thrombi can
detach into the circulation and block blood vessels in the heart or brain, resulting in a
heart attack or ischemic stroke99,103,105. This disease process is the leading cause of death
world-wide and is the number two cause of death in Canada where it accounts for 30%
of mortalities annually106. Atherosclerosis is driven by both resident and
haematopoietically-derived macrophages, with these macrophages acting as the
predominant efferocytic cell type in the heart3,107. These macrophages rely on MERTK
for efferocytosis, which normally acts to prevent atherosclerosis by removing
cholesterol-laden foam cells before they accumulate into an atherosclerotic
plaque99,103,105. Why efferocytic activity is lost in the heart of atherosclerosis patients
remains unclear, but MERTK is linked to this process in several ways. MERTK is
known to be cleaved and shed by an unidentified metalloprotease in atherosclerosis
patients, with mice lacking this cleavage site being resistant to disease 108. In humans, a
number of mutations to MERTK and its opsonin Gas6 are associated with earlier disease
onset and accelerated disease progression109,110 (Table 1). Likewise, restoring effective
efferocytosis can reverse disease, resulting in plaque regression. Indeed, therapies
targeting the “don’t eat me” receptor CD47 have shown great promise in inducing
plaque regression111.
Community-acquired pneumonia (CAP) is characterized by inflammation and
consolidation of lung tissue due to an infectious agent. The predominant pathogen in
CAP is Streptococcus pneumoniae. A portion of people suffer from prolonged
symptoms and even permanent loss of lung function, while recovering from CAP.
During recovery dead and dying neutrophils and epithelium must be cleared by
efferocytosis. In the lung, the clearance of ACs is the normal function of alveolar
macrophages (AMs) and MERTK is the major efferocytic receptor expressed by
AMs112. While the relative importance of MERTK in restoring lung function has not
been completely elucidated, in mice MERTK is known to dampen inflammation in
response to bacterial products113, and MERTK deficiency results in more severe disease
with greater inflammation114.
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Table 1:SNPs in MERTK and Gas6

SNP

Gene

Disease

rs869016

Mertk

Atherosclerosis

rs8191974

Gas6

Atherosclerosis

rs1803628

Gas6

SLE

rs1131244

Mertk

Retinitis Pigmentosa

rs867311

Mertk

Multiple Sclerosis

rs17174870

Mertk

Multiple Sclerosis

rs1516629

Mertk

Multiple Sclerosis
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In humans, the role of MERTK in the recovery from pneumonia is not established,
however, the efferocytic capacity of alveolar macrophages is the only patient feature
known to correlate with recovery115.Given the relatively low expression of other
efferocytic receptors in the lung, it seems likely that MERTK will play an important role
in the recovery from pneumonia. Efferocytosis enables a phagocyte to remove an AC in
a manner which prevents inflammation and autoimmunity. Thus, it is not surprising that
failed efferocytosis is linked to multiple autoimmune diseases such as systemic lupus
erythematosus (SLE), rheumatoid arthritis, and multiple sclerosis (Table 1).
SLE is a chronic autoimmune disease characterized by production of autoantibody,
affecting multiple system including nervous, cardiac, renal and respiratory. Inefficient
clearance of apoptotic cells and their accumulation in tissue is thought to be a
contributing factor to the autoimmune disturbance in SLE by increasing the availability
of potential self antigens116. TAM triple knockout (TKO) and MerTK-/- mice develop
SLE like clinical symptoms due to the induction of autoimmune anti-nuclear antibodies
driven by the inflammation and release of self-antigens that results from secondary
necrosis117–119. Moreover, in human, SNPs in MERTK and Gas6 are linked to increase
risk of SLE and multiple sclerosis7,120.

1.8 Role of Integrins in Efferocytosis
Often, multiple receptors cooperate to induce efferocytosis, with several studies
indicating that MERTK requires integrin co-receptors to mediate the engulfment of an
AC121–124. Integrins are heterodimeric type 1 transmembrane proteins comprised of α/β
heterodimers, with each subunit consisting of large ectodomains and short transmembrane and cytoplasmic domains. There are 18 α subunits and 8 β subunits, which
dimerize to form 24 distinct integrin pairs125–127. Integrins are capable of a unique
bidirectional signaling mechanism, allowing for signals to be passed from the cytosol-toextracellular environment (inside-out signaling) in the form of integrin affinity changes,
and for ligation of extracellular ligands to be detected via activation of intracellular
signaling cascades (outside-in signaling)128,129. Through this bi-directional signaling
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integrins regulate numerous cellular processes ranging from adhesion, migration,
proliferation, survival, differentiation, phagocytosis, and cytoskeletal organization 130.
Integrins can regulate their ligand affinity through changes in the conformation of the
heterodimer and can take on three different conformations: low, intermediate and high
ligand affinity128(Figure 2). Typically, integrins are in an inactive state, during which
they do not signal and exhibit low ligand affinity. In this state, the extracellular domain
is folded, masking the ligand binding site. In this conformation the integrin headpiece is
in close proximity to the cell membrane, and the cytoplasmic tails of the α and β
subunits are closely apposed. When activated, integrins transition through an
intermediary-affinity state131,132, where the integrin extends, but where the ligand
binding site in the headpiece remains closed. This conformation exhibits intermediate
affinity and is the state in which an integrin is receptive to ligand binding. Upon ligand
binding, the conformation of the headgroup changes, increasing ligand affinity and
stabilizing the integrin-ligand complex; these processes also lead to separation of the
intracellular tails128,131. These conformational changes also drive bidirectional signaling
through the integrin. The transition from low- to intermediary-affinity states is mediated
by “inside-out signaling”, induced by the binding of the cytoskeletal protein talin to the
integrin β-chain NPX[Y/F] motif. This signaling also increases the diffusion of
integrins, allowing for integrin clustering and a concurrent increase in integrin avidity,
thus further enhancing integrin-ligand interactions.
Outside-in signaling is triggered when intermediary affinity integrins bind to ligands.
The resulting conformational changes lead to separation of the integrin intracellular tails,
thus enabling the recruitment of a large network of proteins, leading to the local
reorganization of the actin cytoskeleton. Regulators of outside-in signaling include focal
adhesion kinase (FAK), Rho GTP-binding proteins, and adaptor proteins such as Cas,
Crk, and paxillin133.
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A) Closed
headpiece (bent)

B) Closed headpiece
(extended)

C) Open headpiece
(extended)

Figure 2: Schematic of Integrin structure and conformational states. Integrins can
take on three conformational states: A) The low-affinity (inactive) conformation with
closed headpiece and closely apposed intracellular tails, B) the intermediary-affinity
extended conformation with closed headpiece, and C) the high-affinity (active) extended
conformation with open headpiece and separated intracellular tails.
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1.9 Linking TAM Signaling to Integrins
While a number of studies indicate that TAM receptors require integrins to mediate
effective efferocytosis134, it has not yet been demonstrated how TAMs cooperate with
integrins. Based on canonical phagocytic and integrin signaling pathways, there are two
pathways we hypothesize may be involved (Figure 3). TAMs have been shown to
activate PI3K signaling, with the product of this pathway, PIP 3, known to activate
integrin-linked kinase (ILK). ILK contains a PIP 3 binding PH domain, allowing it to be
recruited to areas of active PI3K signaling135. Here, ILK can bind to integrins
intracellular tails and multiple other signaling molecules, creating a complex which can
drive integrins from a low- to intermediary-affinity state. ILK can also be directly
activated by RTKs, through interactions with NCK-2 and PINCH, although this
interaction has not been shown with TAM receptors136,137. Secondly, assuming that
TAMs activate the same canonical Src-family kinase pathway as other phagocytic
receptors, TAMs should be able to activate FAK directly 134,138, independent of integrin
outside-in signaling. This activation of FAK can promote the transition of integrins to
the high-affinity state43. However, none of these integrin-activating pathways have been
explicitly shown to be activated by MERTK or other TAM receptors and remain entirely
hypothetical at this time. Unpublished data from our lab has demonstrated that, in
macrophages, MERTK absolutely requires integrins for its efferocytic function. These
data suggest that MERTK first recognizes the ACs and then activate integrins to mediate
the actual engulfment of the AC (Figure 4A). Indeed, artificially activating integrins
with Mn2+ bypasses the need for MERTK in mediating the uptake of ACs, while
inhibiting integrin activation prevents AC uptake but not binding. Likewise, data from
our lab demonstrated that MERTK is present in large pre-formed clusters on the cell
surface139, with preliminary data showing that these clusters contain MERTK and β 2
integrins (Figure 4B).
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Gas6/Pros

TAM receptor

Integrin

Figure 3: Hypothetical Model of Integrin Activation and Efferocytic Signaling by
TAM Receptors. Binding of TAM receptor to it’s opsonin leads to autophosphorylation
of its tyrosine kinase domain. The phosphorylated kinase domain is recognized by Grb2,
which recruits PI3K, which in turn phosphorylates PI(4,5)P 2 to form PIP3. PIP3 activates
ILK, thus activating integrins. Alternatively, TAM activation may activate Src-family
kinases, which through phosphorylation of FAK, can activate integrins 43.
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A)

Figure 4: Role of Integrins in MERTK Function. A) Efferocytosis assays were
performed using 5 μm diameter targets coated in Gas6 (MERTK-specific targets) and/or
sCD93 (αxβ2 -specific targets) and beads that were either bound or engulfed quantified.
Beads with only integrin ligands and cells lacking MERTK (siMER) were unable to
bind or engulf beads, indicating that MERTK is required for AC recognition. Beads
coated only in MERTK-specific ligands and cells lacking αx were bound but not
internalized, indicating that integrins are required for engulfment. Beads coated in
ligands for both receptors were effectively internalized, as were integrin-specific beads
when integrins were artificially activated with Mn 2+, consistent with MERTK acting as a
recognition receptor, and integrins as an engulfment receptor. B) Super-resolution (~20
nm resolution) image of MERTK (magenta) and β 2 integrin (green) on a human
macrophage. Clustering analysis, which measures enrichment of closely apposed
MERTK:β2 molecules, identified co-clustering in regions 45 nm in radius Scale bars
represent 1 μm. Data quantifies or is representative of a minimum of 10 images collected
in one experiment, and is courtesy of Dr. Bryan Heit and Amanda Evans.
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1.10 Role of MERTK in Efferocytosis
While the members of the TAM family share similar structure and function with 40-50%
amino acid sequence homology, MERTK appears to be the most important member of
the TAM family. MERTK mutation and deficiency, but not mutation or deficiency of
Axl or Tyro3, is associated with a number of pathologies. MERTK deficiency results in
retinitis pigmentosa, a progressive form of blindness caused by a failure to clear aging
rod cells from the retina, while mutations in MERTK lead to an increased risk of
atherosclerosis, multiple sclerosis and other autoimmune disorders. In contrast, mutation
or loss of Axl and Tyro3 do not appear to have a profound effect on humans 110,140.
Mouse models show a similar trend – MERTK knockout mice develop retinitis
pigmentosa and experience progressive male infertility, while Axl and Tyro3 animals
present with no obvious phenotype. Even the triple TAM knockout mouse has a
phenotype only slightly more deleterious than a MERTK single knockout, with these
animals developing male infertility slightly faster than the MERTK knockout
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. Ergo,

in my thesis I am focusing on MERTK, as in both mice and human it appears to be the
most important member of the TAM family. However, the shared structure and signaling
of the TAM receptors makes it likely that my results will be relevant to the function of
all TAM receptors.

1.11 Hypothesis and Aims
Despite MERTK’s significant clinical importance, its signaling pathway is yet to be
elucidated. However, the dependence of MERTK on integrins and its activation of PI3K
signaling leads us to we hypothesize that MERTK activates β2 integrins in order to
mediate engulfment of ACs via a non-canonical phagocytic signaling pathway. To
test this hypothesis, I propose the following aims:
Aim 1: Identify the proteins associated with MERTK and establish their role in the
MERTK-mediated efferocytosis.
Aim 2: Determine how MERTK regulates integrin affinity.
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Chapter 2

2

Materials and Methods

2.1 Materials
THP-1 cells were obtained from ATCC. HeLa cells were gifts from Dr. Jimmy Dikeakos
(University of Western Ontario). HA-MERTK construct (HA-MERTK-Cos7) were
generated by Angela Vrieze. Roswell Park Memorial Institute (RPMI), Dulbecco’s
Modified Eagle Medium (DMEM), and Fetal Bovine Serum (FBS) were purchased from
Wisent (Saint-Jean-Baptiste, Canada), Trypsin-EDTA and antibiotic/antimycotic were
purchased from Corning (Manassas, Virginia). #1.5 thickness round cover slips and 16%
paraformaldehyde (PFA) were purchased from Electron Microscopy Supplies (Hatfield,
Pennsylvania). GenJet Plus was purchased from Frogga Bio. Hoechst, Permafluor, T4
DNA ligase, Phusion DNA polymerase were purchased from Thermo Fisher Scientific.
Protein A/G beads, polystyrene beads, and silica beads were purchased from Bangs
Laboratories, Inc. (Fishers, Indiana) and lipids and biotin PE from Avanti Polar Lipids,
Inc. (Alabaster, Alabama). Gas6, restriction enzymes and goat anti-mouse MERTK
antibody (AF591) were purchased from R&D (Minneapolis, MN). FITC anti-human
CD18 antibody and FITC anti-human CD11c antibody was purchased from Biolegend.
CD11b Monoclonal Antibody Alexa Fluor 488 and Octadecyl rhodamine B (ORB) was
purchased from Invitrogen. Rabbit anti-human MERTK antibody (D21F11) was
purchased from Cell Signaling Technology (Danvers, Massachusetts). Fluorescent
secondary antibodies were purchased from Developmental Studies Hybridoma Bank
(Iowa City, Iowa), and Jackson Immuno Research Laboratories, Inc. (West Grove,
Pennsylvania). Mouse anti-HA (12CA5) was purchased from Santa Cruz (Dallas,
Texas). Anti-phosphotyrosine (4G10) antibody and ILK inhibitor were purchased from
EMD-millipore. PF-00562271 was purchased from Sigma-Aldrich and rest of the
pharmacological inhibitors such as PP1, Syk Inhibitor, Ly294002, Wortmannin, SB
203580 were purchased from Cayman Chemical. Phorbol 12-Myristate 13-Acetate
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(PMA) and rest of the chemicals were purchased from BioShop Canada (Mississauga,
Canada). Mini-PROTEAN TGX Precast Gel was purchased from Bio-rad. Matlab
software was purchased from MathWorks (Natick, Massachusetts). Prism software was
purchased from Graphpad (La Jolla, California). ImageJ was downloaded from the NIH
(www.imagej.nih.gov/ij/).

2.2 Cell Culture and Transfection
HeLa cells and HA-MERTK-COS-7 were maintained in RPMI supplemented with 10%
FBS and DMEM supplemented with 10% FBS respectively. Cells were split at 80%
confluency by washing once with phosphate buffered saline (PBS: 0.9% NaCl, 10mM
Na2HPO4, 2 mM KH2PO4, pH 7.4) followed by a 5 min incubation in trypsin-EDTA
and resuspension in either RPMI or DMEM + 10% FBS. For imaging, cells were seeded
into 12-well tissue culture plate with #1.5 thickness 18 mm diameter coverslips, 1 ml of
RPMI or DMEM + 10% FBS added, and 100 μl of the cell suspension added dropwise
to each well. For FERT experiments (transgene approach), 12- 24 h later the cells were
transfected with the desired construct according to manufacturer’s protocol. Briefly, for
each well, two tubes of 38 μl serum-free DMEM were prepared. Then, 2 μl of GenJet
Plus was added to one tube and 1 μg of DNA was added to the other tube. Diluted
GenJet Plus reagent was added to the diluted DNA solution. Following brief vortex, the
mixture was incubated for 10-15 minutes at room temperature to allow the DNA: GenJet
Plus complexes to form. Finally, the mixture was added drop wise to the desired well
and incubated 18-24 hours.

2.3 THP-1 Cell Culture and Differentiation
THP-1 cells were maintained in RPMI supplemented with 10% FBS at 37°C in 5%
CO2. Cells were split upon reaching 80% confluency. For PMA treatment, THP-1 cells
were centrifuged and resuspended in pre-warmed RPMI to a concentration of
approximately 2.5 x 105 cells/ml. PMA at a concentration of 100 ng/ml was then added
to the cells. For assays, cells were then seeded into12-well tissue culture plate with #1.5
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thickness 18 mm diameter coverslips. THP-1 monocytes were then differentiated into
macrophages with for 72 hours prior experiment.

2.4

RNA Sequencing and RPKM Value

After total RNA was prepared and sequenced, NanoDrop was used to quantify RNA.
2100 Bioanalyzer Instrument and RNA 6000 Nani kit were used to ensure RNA quality.
Samples below an A260/280 of 1.5 and/or RIN of 7 were rejected from analysis. These
samples were then processed using Vazyme VAHTS Total RNA-seq Library Prep Kit
for Illumina. Following the analysis of Fastq data files, the sequences were aligned to
the Homo sapiens genome and annotated. Gene Specific Analysis was used to identify
differentially expressed genes.

2.5 Reversible Cross-Link Immunoprecipitation Procedure
HA-MERTK-COS-7 Cells were cultured and seeded as mentioned previously. Cells
were washed twice with PBS. Following removal of PBS, 1 ml of crosslinker solution
(cross-linkers were freshly prepared as a 20 mM solution in Dimethyl Sulfoxide
(DMSO) and diluted to the indicated final working concentrations in PBS, pH 7.4) was
added to each well and incubated at room temperature for 30 minutes. 1ml of quenching
buffer (20 mM Tris-Cl pH 7.4, 5 mM L-Cysteine) was added to each well following the
removal of the crosslinker solution and incubated for another 10 minutes at room
temperature. Cells were then lysed with RIPA buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS) supplemented with protease and
phosphatase inhibitors and the lysate was incubated with 10µl Mouse anti-HA (12CA5)
for 2 hours with rotation. 10µl Protein-A beads were then added and incubated for
another hour. The beads were then centrifuged and washed twice with 1 mL RIPA
buffer, supplemented with protease and phosphatase inhibitors. Following the wash,
beads were collected in 60µl of Laemmli buffers supplemented with 50 mM DTT and
protease and phosphatase inhibitor and boiled for 5 minutes and centrifuged at
maximum speed for 5 minutes and pelleted. For mass spectrometry analysis, elutes were
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separated by SDS-PAGE on a Mini-PROTEAN TGX Precast Gels and stained with
colloidal Coomassie stain141.

2.6 Phagocytosis Assay
THP-1 cells were plated at approximately 2.5 x 105 cells per 18mm coverslip on a 12well plate and differentiated with PMA for 72 hours prior experiment. For inhibition of
IgG-mediated phagocytosis, the cells were either left untreated or treated with 2.5μM
LY294002, 100nM Wortmannin, 30μM PP1, 100nM Syk inhibitor, 10µM SB 203580,
2µM ILK inhibitor and 25 µM PF-00562271 for 15 minutes (Table 2). Whole human
IgG-coated beads were prepared by mixing 10μL of 3.17μm polystyrene microsphere
beads with 100μL of PBS and 10μL human IgG then rotating for 2 hours at room
temperature. Beads were washed twice and re-suspended with 100μL of PBS and then
3μL of coated beads was added to each well in 1mL of serum-free RPMI in presence of
the inhibitors. The cells were centrifuged at 400 x g for 2 minutes then incubated at
37°C with 5% CO2 for 60 minutes and washed three times with PBS at the end of the
incubation period. External beads were labeled using 1:500 goat anti-human Dylight 488
antibody in PBS for 20 minutes with 1:10,000 Hoechst for 5 minutes and washed three
times with PBS and fixed for 15 min with 4% PFA, mounted on slides with imaging
buffer and imaged using a Leica DMI6000B microscope equipped with a photometrics
Evolve-512 delta EM-CCD camera and Chroma Sedat Quad filter set running Leica
LAX software widefield microscope. Phagocytic index was calculated by dividing the
total number of internalized beads by total number of macrophages counted. A
minimum of 30 macrophages were counted for each condition (untreated, LY294002,
Wortmannin, PP1, Syk inhibitor, SB 203580, ILK inhibitor, PF-00562271 treated) in
one experiment. Images were analyzed on Fiji ImageJ software (http://fiji.sc/Fiji).
Graphs were created using GraphPad Prism.

2.7 Efferocytosis Assay
THP-1 cells were prepared and differentiated as indicated in section 2.3, 3 days prior to
the beginning of the experiment. For inhibition of MERTK-mediated efferocytosis, the
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Table 2: List of Pharmacological Inhibitor

Proteins

Inhibitors

Source

Catalogue
number

PI3K

LY294002,
Wortmannin

Cayman
Chemical

70920
10010591

SFK

PP1

Cayman
Chemical

14244

Syk

Syk inhibitor

Cayman
Chemical

p38

SB 203580

Cayman
Chemical

13067

ILK

ILK inhibitor, Cpd 22

EMDmillipore

407331

FAK

PF-00562271

SigmaAldrich

PF 562271

14829
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cells were either left untreated or treated with 2.5μM LY294002, 100nM Wortmannin,
30μM PP1, 100nM Syk inhibitor, 10µM SB 203580, 2µM ILK inhibitor and 25µM PF00562271 for 15 minutes (Table 2). Apoptotic mimic beads were prepared by
combining 10 μL of 3.17μm polystyrene microsphere beads with 114 μL of
phosphatidylcholine, 84 μL of phosphatidylserine and 4 μL of biotinylated
phosphatidylethanolamine (biotin-PE)142 Coated beads were then dried by nitrogen gas,
washed twice in 500 μL PBS by centrifuging at 4,500 x g for 1 min and resuspended in
100 μL PBS. Opsonized PtdSer/PC beads were prepared for each well by rotating 3 μL
of bead solution with 3μL of recombinant Gas6 in a total of 25µl PBS for 2 hours at
room temperature or overnight at 4°C and washed in PBS. Opsonized beads were then
added to each well in 1mL of serum-free RPMI in presence of the inhibitors. The cells
were centrifuged at 400 x g for 2 minutes so that the beads come in contact with the
cells. Cells were then incubated for 60 minutes at 37°C with 5% CO2. After 1hour
incubation, cells were washed three times with PBS. External beads were labeled using
1:500 streptavidin-Alexa647 in PBS for 20 minutes with 1:10,000 Hoechst for 5 minutes
and washed three times with PBS and fixed for 15 min with 4% PFA, mounted on slides
with imaging buffer and imaged using a Leica DMI6000B microscope equipped with a
photometrics Evolve-512 delta and EM-CCD camera and Chroma Sedat Quad filter set
running Leica LAX software. Efferocytic index was calculated by dividing the total
number of internalized beads by total number of macrophages counted. Images were
analyzed on Fiji ImageJ software (http://fiji.sc/Fiji). Graph was created using GraphPad
Prism.

2.8 Immunostaining
THP-1 cells were washed with PBS and fixed with 4% PFA in PBS at 10°C for 20
minutes. Cells were washed three times with PBS, followed by 1hour incubation with
primary antibody (1 in 200, anti-human MERTK, 1 in 40, FITC anti human CD18, anti
human CD11c and CD11b monoclonal antibody). Cells were then washed with PBS
three times and stained using 1in 200 fluorescently tagged secondary antibodies. Lastly,
cells were washed with PBS three times and incubated in1:10,000 Hoechst in PBS for 5
mins. After a final PBS wash, coverslips were mounted on glass slides and imaged using
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Leica DMI6000B microscope equipped with a photometrics Evolve-512 delta and EMCCD camera and Chroma Sedat Quad filter set running Leica LAX software.

2.9 DNA Plasmids and Construct
Cytoplasmically-labeled αx -mTurquoise2 and β2 -mVenus were generated using the
pmTurquoise2-N1 and pmVenus-N1, respectively. For αx -mTurquoise2, PCR extension
was performed using cDNA of the wild-type αx subunit as a template with the upstream
primer 5’-gtcga cggta ccgcg ggccc ATGAC CAGGA CCAGG GCAGC A-3’ and
the downstream primer 5’-ggtgg cgacc ggtgg atccc ATTTC TCACT GGGCG
GGCTG GG-3’. The amplified PCR product was digested with SmaI for 2 hours at 37ºC,

then ligated overnight at 16°C using T4 DNA ligase. DNA sequencing was performed at the
London Genomics Centre (Robarts Research Institute, London, Canada). For β2 -mVenus,

β2 integrin was digested with HindIII and AgeI and inserted into pmVenus.

2.10 Transgene-Based FRET Assay
Hela cells were seeded and transfected following the manufacturers protocol. Briefly, as
a negative control, cells were transfected with mTurquoise2 and mVenus on separate
plasmids. As a positive control, we transfected Hela cells with a mTurquoise2-mVenus
linker construct. In the biological sample, HeLa cells were transfected with transgenes
comprised of cytoplasmically-labeled αx- mTurquise2 and β2-mvenus143. Transfected
samples were then incubated for 24 hours and imaged with Leica DMI6000B
microscope equipped with a photometrics Evolve-512 delta and EM-CCD camera and
Chroma Sedat Quad filter set running Leica LAX software. Filters for FRET channels,
Idd-Ex: 430; Em: 470/24, Ida-Ex: 430; Em: 535/50 and Iaa-Ex: 490; Em:535/50. Images
were analyzed using Matlab software.

2.11 Antibody-Based FRET Analysis
THP-1 cells were plated and differentiated as described previously in section 2.3. At the
day of the experiment cells were cooled at 10ºC for 10 minutes. Cells were then washed
3 times with PBS and incubated with 1 in 40, FITC anti human CD18 antibody
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(10µg/ml) for 20 minutes at 10ºC. After 20 minutes, cells were washed again with PBS
and incubated with ORB (100nM) plus 1 in 200, goat anti-mouse 488 antibody
(0.8mg/ml) for another 20 minutes. At the end of the incubation period cells were
washed with PBS and pharmacological inhibitors were added at desired concentration as
mentioned in section 2.6 and incubated at 37ºC for 15 minutes. Then Gas6 coated beads
to each sample were added and imaged using Leica DMI6000B microscope equipped
with a photometrics Evolve-512 delta and EM-CCD camera and Chroma Sedat Quad
filter set running Leica LAX software widefield microscope and filters for FRET
chnnels, Idd-Ex: 490; Em: 535/50, Ida-Ex: 490; Em: 605/52 and Iaa-Ex: 500/40; Em:
605/52. Images were analyzed on Fiji ImageJ software (http://fiji.sc/Fiji). GraphPad
Prism was used to create graphs.

2.12 Integrin Activation with Mn2+
For antibody-based integrin FRET with Mn2+, THP-1 cells were seeded, differentiated
and stained with FITC anti human CD18 antibody and ORB plus secondary antibody, as
described in section 2.11. Following the incubation with ORB, cells were washed three
times with PBS and imaged. Then Mn2+(1mM) solution was added to the well and
imaged again using Leica DMI6000B microscope equipped with a photometrics Evolve512 delta and EM-CCD camera and Chroma Sedat Quad filter set running Leica LAX
software. Images were analysed were analyzed on Fiji ImageJ software
(http://fiji.sc/Fiji). Graph was created using GraphPad Prism.

2.13 Statistical Analysis
Data are presented as the mean ± SEM. Two-tailed student’s t-test and Kruskal Willis
test with Dunn's multiple comparison was performed to determine the statistical
significance of differences between groups.
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Chapter 3
3 Results
3.1 Expression of Endogenous MERTK & β 2 Integrin in
THP-1 Cells
To address my hypothesis, I needed to identify a cell line with endogenous expression of
MerTK and β2 integrin. First, I analyzed a THP-1 cell RNAseq dataset produced recently
by our lab (unpublished data, courtesy of Mara Rosoga), identifying the expression level
of β2 integrins and multiple efferocytic receptors (Figure 5). All β2 integrins other than
αD were expressed by these cells, as well as several efferocytic receptors. Of the latter,
MERTK was the most highly expressed TAM receptor. To confirm expression of
MERTK and β2, I performed immunostaining on THP-1 cells. Both undifferentiated
(monocytic) and PMA-differentiated (macrophage-like) THP-1 cells expressed MerTK,
and integrins (Figure 6), consistent with previous reports144.

3.2 Identification of the MERTK Signalosome
We expect MERTK to share components of the canonical phagocytic signaling pathway,
as well as to engage novel signaling pathways to modulate the activation of integrins. As
mentioned earlier, the phagocytic signaling pathway requires the activation of SFK and
the Rho-family GTPases Rac1 and CDC42 to induce actin reorganization, with larger
particulates (>1 µm) requiring amplification of this actin reorganization pathway via
PI3K signaling24,62–66. Since TAM receptors are also able to induce the uptake of large
ACs it is likely that they activate these pathways as well.
Moreover, a recent publication from our lab investigated MERTKs structure and
function on macrophages. In that study we demonstrated that MERTK is part of a large
cell surface cluster, and that MERTKs activity is highly dependant on the formation of
these clusters145. By immunoprecipitating MERTK and identifying proteins that co-

RPKM

RPKM
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Integrins

Efferocytic Receptor

Figure 5: Efferocytic Receptor and Integrin mRNA Expression in THP-1 Cells.
RNAseq data from PMA-differentiated THP-1 macrophages was used to quantify the
expression level of multiple efferocytic receptors and β 2 integrins. Data are presented as
mean Reads Per Kilobase of transcript, per Million mapped reads (RPKM) ± SEM from
three independent experiment. Data courtesy of Mara Rosoga.

29

A)
Hoechst

MERTK

Hoechst

MERTK

B)

30

C)

Hoechst

β2 Integrin

Hoechst

αx Integrin

Hoechst

αm Integrin

D)

E)

31

Figure 6: Expression of MERTK & Integrin in THP-1 Cell Line. A) PMA
differentiated & B) undifferentiated THP-1 cells immunostained with anti-human
MerTK and counterstained with Hoechst, showing the typical punctate distribution of
MERTK. C-E) Differentiated THP-1 cells were stained with FITC anti-human CD18
(β2), FITC anti-human CD11c (αx) and CD11b (αm) monoclonal antibody respectively
and counterstained with Hoechst. Image is representative of three independent
experiments. Scale bars represent 1μm.
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precipitated by mass spectrometry, we have identified a putative MERTK signalosome
within these preformed clusters (Table 3). This analysis identified a variety of signaling
molecules that are consistent with the canonical phagocytosis signaling pathway
including PI3K and several SFK, as well as proteins consistent with a novel integrinactivating pathway including several integrins and integrin-associated signaling
molecules such as ILK. This is consistent with previous literature showing that MERTK
may require integrins as co-receptors146. Based on our data and literature, we have
assembled a hypothetical MERTK signaling pathway (Figure 7).
This hypothetical pathway identifies four major signaling pathways that are potentially
central to MERTK function. Firstly, the PI3K pathway, which is usually required to
engulf large targets such as apoptotic cells. Secondly, the SFK pathway which is
essential for any type of phagocytosis and may link integrins to MERTK function via
regulation of FAK. Thirdly, the p38 MAPK pathway is of interest due to its involvement
in regulating inflammation, and lastly, the ILK pathway as this may be the pathway that
links MERTK signaling to integrin activation63,121,147–149.

3.3 Optimization of Pharmacological Inhibitor Concentration
To assess these four pathways of interest, we identified pharmacological inhibitors
previously established to block these pathways with reasonable specificity. The specific
proteins targeted, and their corresponding inhibitors are identified in Figure 8 and Table
2
Once the proteins were identified, our objective was to determine their role in MERTK
mediated efferocytosis through pharmacological inhibition150–153. To optimize the
inhibitory concentration of these pharmacological inhibitors, we performed doseefferocytic response analyses (Figure 9). THP-1 cells were treated with different
inhibitors and incubated with Gas6 coated beads in presence of these inhibitors. All
inhibitors suppressed efferocytosis in a dose dependant manner (Figure 9). However,
while most of the inhibitors blocked efferocytosis at concentrations near their reported
IC50,
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Table 3: Putative Components of the MERTK Identified by
Immunoprecipitation/Mass Spectrometry

Peaks
Score

Coverage

Integrins
β integrin

99.1

10%

α integrin

97.2

8%

ILK
Kinases

99.0

13%

Erk1
MAP4K4
RASA2
AKAP9
PI3K Signaling
PI3R4
PIP4K2B
PI4C2
SFKs
Lyn
Fgr
Hck
Fyn
GTPases
RhoE
IQGAP1
ARHGAP9

72.6
94.6
69.0
64.1

7%
5%
3%
14%

87.7
61.2
58.5

8%
3%
4%

90.2
96.3
97.5
91.7

5%
8%
11%
7%

61.4
52.7
49.6

6%
24%
5%

Protein

1
x
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Gas6/Pros

MERTK

αXβ₂

Figure 7: Hypothetical MERTK Signaling Pathway Based on Mass Spectrometry
Results. Proteins highlighted in green are the proteins identified in mass spectrometry
including αxβ₂ integrin. Proteins/lipids in blue are hypothetical members of this pathway
based on known signlaing pathways downstream of non-efferocytic receptors.
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Gas6/Pros

MERTK

αXβ₂

Figure 8: Inhibitor Approach Used to Assess the Role of Key Signaling Molecules,
in our hypothetical MERTK signaling pathway. Targeted proteins are highlighted in
yellow; table lists the corresponding pharmacological inhibitors.
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PI3K
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Efferocytic Index (%)

PI3K
LY294002
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Syk
SykI

Efferocytic Index (%)

SFK
PP1

(nM)
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37

ILK
ILKI

Efferocytic Index (%)

p38
SB203580

(µM)

(µM)

Efferocytic Index (%)

FAK
PF00562271

(µM)

Figure 9: Determination of Appropriate Inhibitor Doses. Efferocytosis assays were
used to identify the minimum inhibitory dose of each inhibitor. Data are presented as
mean ± SEM from one independent experiment.
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the p38 MAPK inhibitor blocked efferocytosis at a concentration more than 100-fold
higher than its reported IC50, likely indicating that this inhibition is due to an off-target
effect66,150,152–154.

3.4 Phagocytosis Assay with Pharmacological Inhibitors
Because many of the targeted proteins are members of the canonical phagocytic
signaling pathway, I confirmed efficacy of the inhibitors in an assay of FcγR mediated
phagocytosis, using IgG coated beads as phagocytic targets 26. As expected, untreated
cells were highly phagocytic, with this activity blocked by inhibitors of PI3K
(LY294002, Wortmannin) and Syk (SykI) (Figure 10 A-C, E & I). Unexpectedly, the
SFK inhibitor PP1 did not block phagocytosis in this cell type ( Figure 10 D), even
though we observed inhibition of phagocytosis with the same inhibitor in other
macrophage cell lines26,155. As expected, phagocytosis was not blocked by inhibitors of
p38 (SB203580), ILK (ILKI), or FAK (PF00562271) (Figure 10 F-I).

3.5 MERTK Mediated Efferocytosis Requires Both
Canonical & Non-Canonical Phagocytic Signaling Molecules
Using beads containing a MERTK-specific ligand (Gas6), I next assessed the role of
proteins identified previously in our lab as part of the MERTK signalosome (Figure 8).
Here, we used our well established model which uses bead-based mimics of ACs to
accurately quantify efferocytic activity142,156. THP-1 cells were treated with or without
inhibitors and fed 3.17 µm beads coated in an AC-mimicking lipid mixture (19.8%
PtdSer, 80% PtdChol, and 0.2% biotin-PE), and opsonized with Gas6. At the end of the
incubation period, non-internalized beads were labeled with streptavidin, which binds
the biotin-PE of non-internalized beads, allowing a clear delineation between
internalized and non-internalized beads. The cells were then imaged and uptake of Gas6
coated beads by THP-1 cells quantified (Figure 11). We found that untreated THP-1
cells readily efferocytosed these beads, while cells treated with inhibitors of PI3Ks and
SFKs were incapable of efferocytosis, consistent with a role for canonical phagocytic
signaling. Interestingly, both ILK and FAK inhibitors blocked efferocytosis,
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Figure 10: Quantification of the effect of inhibition on FcγR (IgG coated beads) mediated phagocytosis A) Images of FcγR -mediated phagocytosis on untreated THP-1
cells. B-H) Images of FcγR -mediated phagocytosis on B & C) various components of
PI3K (LY294002, Wortmannin) D) SFK (PP1) E) Syk (SykI) F) p38 (SB203580) G)
ILK (ILKI) H) FAK (PF-00562271) inhibited THP-1 cells. The DIC image showing all
the beads added to the cells, the nuclei were stained with Hoechst, non-internalized
beads detected using Dylight-488 conjugated secondary antibody and the merge image
displays clear delineation of non-internalized versus phagocytosed beads. I) Effect of
Inhibition of various components of the PI3K pathway (Wortmannin, LY294002), Srcfamily kinase (PP1), Syk (SykI), P38 MAPK (SB203580) and ILK (ILKI), FAK
(PF00562271) were assessed on the phagocytosis of IgG-opsonized beads (FcγR). Data
is presented as mean ± SEM from three independent experiments with 90 cells counted
per condition. * = P < 0.05 compared to UT, Kruskal Willis test with Dunn's multiple
comparison test. Scale bars represent 10 µm.

43

DIC

Nuclei

Non- internalized
beads

Untreated

A)

LY

B)

Wort

C)

PP1

D)

Merge

44

DIC

Nuclei

Non- internalized
beads

SykI

E)

SB

F)

ILKI

G)

PF

H)

Merge

45

I)

Efferocytic Index

Untreated
PI3 Kinase pathway
Src/Syk pathway
p38 MAPK
Integrin

*

*
*

*

Inhibitors

*

46

Figure 11: Quantification of the effect of inhibition on MERTK-mediated
efferocytosis. A) Images of MERTK-mediated efferocytosis on untreated THP-1 cells
as positive control. B-H) Images of MERTK-mediated efferocytosis on B & C) various
components of PI3K (LY294002, Wortmannin) D) SFK (PP1) E) Syk (SykI) F) p38
(SB203580) G) ILK (ILKI) H) FAK (PF-00562271) inhibited THP-1 cells. The DIC
image showing all the beads added to the cells, the nuclei were stained with Hoechst,
non-internalized beads detected using streptavidin staining and the merge image displays
clear delineation of non-internalized versus efferocytosed beads. I) Effect of Inhibition
of various components of the PI3K pathway (Wortmannin, LY294002), Src-family
kinase (PP1), Syk (SykI), P38 MAPK (SB203580) and ILK (ILKI), FAK (PF00562271)
were assessed on the efferocytosis of Gas6-opsonized beads (MERTK). Data is
presented as mean ± SEM from three independent experiments with 90 cells counted per
condition. * = P < 0.05 compared to UT, Kruskal Willis test with Dunn's multiple
comparison test. Scale bar represents 10 µm.
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demonstrating that MERTK requires both canonical phagocytic signaling and also noncanonical signaling through ILK and FAK. Interestingly, no inhibition was observed in
cells treated with Syk inhibitors, suggesting that the MERTK kinase domain may
replace the role normally played by Syk during phagocytosis. As expected, p38 MAPK
inhibition, when the inhibitor was used at a reasonable concentration (10× its IC 50), had
no effect on efferocytosis.

3.6 Measuring Integrin Activation by Förster Resonance
Energy Transfer
Integrins are obligate heterodimers composed of transmembrane alpha and beta
subunits. The extracellular domains of inactive integrins are folded and display a
conformation that has a low affinity for ligands (Figure 2). Inside-out signaling is
mediated by the binding of the N-terminal head domain of the cytoskeletal protein talin
to the NPX[Y/F] motif in the β-chains intracellular tail. This binding induces a
conformational change in the extracellular domain of the integrin, causing it to unbend
and take on an extended, medium-affinity conformation. Integrin in this conformation
bind to its ligand which induces further conformational changes, resulting in increased
binding to the ligand, and outside-in signaling which results in the separation of the
integrins intracellular tails, binding of various effectors to the active integrin, leading to
integrin-mediated actin reorganization. In the case of MERTK, it is likely that this actin
reorganization is required for the engulfment of the AC, which would explain why
MERTK on its own is capable of mediating the binding, but not the internalization, of
ACs133.
My identification of the MERTK signaling pathway, plus our previous results showing
the requirement for β2 integrins in MERTK function, led us to investigate the role of
MERTK-activated signaling molecules on the activation of β 2 integrins. Measuring
integrin conformational changes is challenging, and generally requires Förster resonance
energy transfer (FRET) for the direct identification of integrin conformational states.
Thus, I used FRET to analyze integrin activation in response to MERTK signaling.
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FRET was described by Theodor Förster as a phenomenon wherein a donor fluorophore
in its excited state transfers its excitation energy to an acceptor fluorophore, causing the
acceptor to fluoresce157. This occurs if the donor and acceptor fluorophores are in close
proximity (typically 10-100 Å) and when the emission spectrum of the donor has a
minimum of 30% spectral overlap with the absorption spectrum of the acceptor
fluorophore143. Owing to its distance sensitivity, FRET is used to investigate interaction
of closely associated molecules, as well as to detect conformational changes in
integrins158,159.
Since most biological molecules are not self-fluorescent, tagging of target molecules
with fluorescent markers is required. There are multiple approaches through which
integrins can be tagged with fluorescent markers in a FRET-compatible format. This
includes transgenic fusion proteins where the intracellular tails of the integrin
heterodimer are labeled with FRET-compatible fluorescent proteins 160, or endogenous
proteins and lipids can be labeled with fluorescent antibodies or lipid-soluble dyes 161.

3.7 Transgene Integrin FRET Approach
We first attempted to measure integrin affinity using a classical integrin-activation
FRET reporter approach160. For this assay, we created two transgenes, comprised of α x
integrin cytoplasmically labeled with mTurquoise2 (donor fluorophore), and β 2cytoplasmically labeled with mVenus (acceptor fluorophore). In their inactive state, the
tail of the integrins are closely apposed, allowing for FRET between mTurquoise2 and
mVenus. Because integrin tails separate during activation128,131, integrin activation can
be quantified by measuring the loss of the FRET signal, following normalization for
donor and acceptor fluorophore expression (Figure 12).

3.8

Generation of the Fluorescent Protein Tagged Integrin

Cytoplasmically-labeled αx-mTurquoise2 and β2-mVenus were generated using the
pmTurquoise2-N1 and pmVenus-N1, respectively (Figure 13). For αx-mTurquoise2,
PCR extension was performed using cDNA of the wild-type α x as a template with the
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Figure 12: Measuring Integrin Activation with FRET. Transgenes comprised of
cytoplasmically-labeled αx-mTurquise2 and β2-mVenus are co-expressed. In their
inactive conformation, the intracellular tails of αx and β2 are closely apposed (left),
allowing for FRET energy transfer between excited mTurquoise2 and mVenus (middle).
In their active conformation, the intracellular tails of α x and β2 separate, reducing FRET
efficiency (right).
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Figure 13: Schematic of the Strategy Used to Clone α x-mTurquoise2 and β2mVenus. αx-mTurquoise2 (top, also known as CD11c) and β2-mVenus (bottom, also
known as CD18).
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upstream primer 5’-gtcga cggta ccgcg ggccc ATGAC CAGGA CCAGG GCAGC
A-3’ and the downstream primer 5’-ggtgg cgacc ggtgg atccc ATTTC TCACT
GGGCG GGCTG GG-3’. The PCR product was digested with SmaI and inserted into

pmTurquoise2-N1. For β 2 -mVenus, β2 integrin was digested with HindIII and AgeI and
inserted into pmVenus-N1 (Figure 13).

3.9 FRET Analysis Using the Transgene Approach
As a negative control, we transfected Hela cells with mTurquoise2 and mVenus as
monomeric proteins on separate plasmids. Without any linker between mTurquoise2 and
mVenus, an mVenus signal could be detected the transfected cell, but no FRET signal
was observed (Figure 14 A).
As a positive control, we transfected Hela cells with a mTurquoise2-mVenus linker
construct, which positioned the fluorophores at a distance with a known FRET
efficiency (43%). Unlike the negative control, a strong FRET signal was observed
throughout the transfected cell (Figure 14 B). Expression of the negative and positive
control showed that we could detect changes in FRET between these two fluorophores.
Next, HeLa cells were transfected with transgenes comprised of cytoplasmically-labeled
αx- mTurquoise2 and β2-mVenus, and a FRET signal consistent with the presence of
inactive integrins was observed (Figure 14 C).The presence of this FRET signal
demonstrated that we could detect integrins in their inactive form, and thus integrin
activation should be quantifiable as a decrease of this FRET signal.
Divalent cation plays a pivotal role in the conformational state of integrins. Ca 2+ is
required to maintain integrins in inactive conformation, with removal of this Ca 2+
rapidly forcing integrins into an active state. Conversely, the addition of Mn 2+ artificially
forces integrin into their active conformation 162. Thus, by adding Mn2+ we should be
able to force integrins into their active conformation, which would be detected as a
decrease in the FRET signal in our reporter system. However, when HeLa expressing
cytoplasmically-labeled αx- mTurquise2 and β2-mVenus were treated with 1 mM
Mn2+(Figure 15), which in other studies was sufficient to induce a conformational
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Figure 14: FRET Test, using donor-normalized FRET. Using constructs expressing
mTurquoise2 and mVenus as separate proteins (Negative Control, A) or as a single
polypeptide (Positive Control, B), we have confirmed that we can detect and quantify
FRET efficiency between these two fluorophores, and that the predicted FRET
efficiency of this pair (43%) is what is predicted, given the spectral overlap of these
fluorophores and the filter sets available on our microscope system. C) A FRET signal is
observed in HeLa expressing cytoplasmically-labeled αx- mTurquoise2 and β2-mVenus,
indicating the presence of integrins in their inactive state. Data are representative of two
independent experiment. Scale bars represent 1µm.
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Figure 15: Failure of the β2 Conformation Reporter System. HeLa cells expressing
cytoplasmically-labeled αx-mTurquoise2 and β2-mVenus did not undergo the expected
quenching of their FRET signal when integrins were forcefully activated by the addition
of 1mM Mn2+. Data are representative of five independent experiment.
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change in β2 integrins162,163, no difference in FRET signal was observed. These
experiments were repeated using a range of Mn2+ concentrations and observation time,
with no change in FRET signal detected in any experiment (data not shown). So while
we were able to detect FRET from our αxβ2 biological sample, we were unable to detect
changes in this FRET signal when we forced integrins into their active conformation
with Mn2+ 162. We believe this lack of change in signal is because the majority of the
ectopically expressed integrin appears to be trapped in the endomembrane system
(Figure 14C, left panel), with the resulting background signal overwhelming the weak
FRET signal produced by the small portion of integrins which trafficked properly to the
plasma membrane. As such, an alternative FRET approach was used to quantify integrin
activation.

3.10 Antibody-Based Integrin FRET
Because ectopic expression of fluorescently-labeled integrins led to the mis-localization
of the integrins, we next used an approach which labels only endogenous, plasma
membrane localized integrins. This should eliminate complications arising from the
ectopic expression of proteins and eliminate all signals from the endomembrane system.
In this assay I labeled the integrin with a FITC-labeled (donor fluorophore) anti-β 2
antibody specific to the headgroup of the β2 integrin. The plasma membrane of the cell
was labeled with the lipophilic acceptor fluorophore, ORB. In their inactive state, the
bent conformation of the integrin should place the FITC-labeled anti-integrin antibody
in close proximity to the plasma membrane, producing a FRET signal with ORB. Upon
activation the integrin extends, moving the FITC molecule past the maximum distance
over which FRET can occur (>10Å), allowing us to detect integrin activation as a
decrease in FRET signal164 (Figure 16).

3.11 Optimization of FRET Labeling
For the antibody/ORB approach to work, integrins must be labeled at or near saturating
levels, to maximize the donor signal, while the membrane must be labeled with the
maximum concentration of acceptor fluorophore possible, in order to maximize

57
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Figure 16: Antibody-Based Integrin FRET. Schematic depicting FRET between FITC
conjugated mAbs and ORB membrane dye in inactive (bent) integrin, and loss of FRET
due to the extension of the integrins extracellular domain.
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FRET potential, while using a concentration of acceptor that does not lead to bleedthrough in the donor channel or self-quenching. First, I optimized β 2 integrin and
membrane labeling, testing a range of antibody and ORB concentrations in order to
identify saturating labeling conditions for the integrin, and highest concentration of ORB
that does not produce bleed-through in the FITC channel (indicative of excimer
formation) or a decrease in ORB signal (indicative of self-quenching). Specifically, the
membrane of THP-1 monocytes was labeled with five different concentrations (4,10, 40,
100 & 400 nM) of ORB, and the resulting samples imaged in the donor (FITC) and
acceptor (ORB) wavelengths (Figure 17 A-E). 100 nM ORB was the highest
concentration that did not produce any bleed through into the FITC channel, with none
of the tested concentrations producing self-quenching. Therefore, 100 nM ORB was
used for all future experiments.
FITC anti human CD18 antibody recognizes the I-like domain of the β 2 subunit165. β2
integrin was labeled with two concentrations (4µg/ml and 10µg/ml) of this antibody and
the higher concentration was used for subsequent experiments (Figure 17 F, G).

3.12 Forced Integrin Activation with Mn2+
2+

Once optimized, I used Mn positive control and live-cell microscopy to force integrins
into the active conformation162, in order to confirm that we could detect integrin
activation using this antibody-based integrin FRET system.
THP-1 cells were treated with 1 mM Mn2+ (Figure 18 A-C) which was reported to be
sufficient to induce a conformational change in β 2 integrins162,163. When compared to
untreated sample, the FRET intensity plot (Figure 18 B) showed a linear time-dependent
reduction of the FRET signal after adding Mn2+, indicating I had activated the integrin,
and demonstrating that this method works.
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Figure 17: Optimization of FRET Labeling. THP-1 cells were stained with Hoechst
and A-E) Membrane was labeled with five concentrations of ORB (4,10, 40, 100 & 400
nM). F-G) β2 integrin was labeled with two concentrations of FITC anti-human CD18
antibody (4µg/ml and 10µg/ml respectively). Labeling concentrations that maximized
the integrin signal and eliminated bleed-through of the ORB signal into the FITC
channel were used. Data are representative of three independent experiment. Scale bars
represent 1µm.
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Figure 18: Forced Integrin Activation with Mn2+. A) Images of THP-1 cells before
and after the addition of Mn2+. Scale bars represent 1µm. B) Time course of FRET
intensity in untreated (black dots) versus Mn2+-treated (grey squares) THP-1
macrophages. C) Effect of Mn2+ on FRET signal at the point of maximum integrin
activation. Data is presented as a representative trace (A) or mean ± SEM (B) from three
independent experiments. ** = p < 0.05, two-tailed Student’s t-test.
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3.13 MERTK Activating β2 Integrins within the Efferocytic
Cup
We next assessed whether we could detect integrin activation in response to a Gas6
(MERTK-activating) beads. PMA differentiated THP-1 cells were incubated with FITC
conjugated CD18 antibody (donor fluorophore), which recognize the headgroup of the
β2 integrin and ORB (acceptor fluorophore) to label the membrane. THP-1 cells were
then fed 3.17 µm silica beads which mimicked the apoptotic cell. Beads were coated
with 19.8% PtdSer, 80% PtdChol, and 0.2% biotin-PE, and opsonized with the MERTK
ligand Gas6. Integrin activation was quantified in the efferocytic cup, and in a region of
membrane on the same cell distal to efferocytic sites. This quantification revealed that
integrin activation occurred locally, within the efferocytic cup (Figure 19A), and that
this activation occurs in the absence of an integrin ligand on the apoptotic mimic beads.
Therefore, MERTK signaling induced by Gas6 is sufficient to induce the local activation
of β2 integrins.
Based on this observation, I then began investigating which of the signaling pathways
identified in Figure 7 were required for MERTK-mediated activation of the β2 integrins.
I performed the antibody-based FRET experiment in the presence of the
pharmacological inhibitors used previously. To measure MERTK-specific integrin
activation, I normalized the FRET signal in the efferocytic cup forming around the
MERTK-specific bead to the FRET signal present in an approximately equal sized area
of membrane distal to the site of efferocytosis (Figure 19). In untreated THP-1 cells a
decrease in the FRET signal of the efferocytic cup was observed, with this signal
consistently below the FRET signal of the membrane distal to the efferocytic cup
(Figure 19A & B). This pattern of integrin activation was also observed in macrophages
treated with pharmacological inhibitors against p38 MAPK (SB203580), SFK (PP1),
and Syk (SykI) (Figure 19, C-E). In contrast, the FRET signal within the phagocytic
cup remained at the level observed in bulk membrane in the presence of inhibitors of
ILK (ILKI), FAK (PF00562271) and PI3K (Wortmannin, LY294002), indicating these
inhibitors prevent the activation of β2 integrins by MERTK (Figure 19, F-I).
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Figure 19: Quantification of Integrin Activation with FRET. (A) Image showing
decrease in the FRET signal in the efferocytic cup in untreated THP-1 cells. Cells were
stained with FITC anti-human CD18 (β2) in yellow (top panel), ORB in purple (middle
panel), bottom panel indicating the FRET channel and the scale on the right
demonstrating the FRET signal; yellow and orange denote increased FRET signal due to
decreased integrin activation and green and teal denote loss of FRET signal due to
integrin activation. At 0 min, the Gas6 coated bead is bound to the membrane. At 2
mins, the efferocytic cup has started to form and this structure is greener compared to
the membrane proximal to it. From 4 to 8 mins timepoints, the bead is undergoing
engulfment and the inside of the efferocytic cup is green due to integrin activation
compared to the proximal membrane. At 10 mins, the efferocytic cup is closed and
finally at 12 mins, the bead is separated from the plasma membrane into cytosol and the
FRET channel indicating the cytosolic structure is green due to activation of integrin.
(B-I) Representative traces of integrin FRET within efferocytic cups versus bulk
membrane. In the DIC images (left) the specific beads/efferocytic cups (coloured
arrows), and the distal membrane region (boxes) presented in the trace are shown.
Traces (right) are colour-coded to match the corresponding efferocytic cup/distal
membrane in the DIC image. Cells are untreated (B), or treated with inhibitors against
p38 MAPK (C), SFK (D), Syk (E), ILK (F), FAK (G), PI3K (H-I). Data is
representative of three independent experiments.
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In untreated cells, maximum integrin activation was observed 15 minutes after
efferocytic cup formation began. Using this time point, we then quantified maximum
integrin activation. As predicted based on the single-cell traces, we observed that
inhibitors of ILK and FAK efficiently blocked integrin activation. Inhibitors of PI3K
signaling (LY294002 and wortmannin) also prevented MERTK mediated integrin
activation (Figure 20). In contrast, the inhibitors against SFKs (PP1), Syk (SykI) and
p38 (SB 203580) had no impact on integrin activation (Figure 20).
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Figure 20: Signaling Pathways Regulating MERTK-Mediated β 2 Integrins
Activation. Effect of Inhibition of various components of the PI3K pathway
(Wortmannin, LY294002), ILK (ILKI), FAK (PF00562271), Src-family kinase (PP1),
Syk (SykI), and p38 MAPK (SB203580) were assessed on the MERTK mediated
activation of β2 integrin. Data is presented as the FRET ratios of individual efferocytic
cups normalized to bulk membrane, plus the mean of each group, aggregated from three
independent experiment. * = P < 0.05 compared to UT, Kruskal Willis test with Dunn's
multiple comparison test.
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Chapter 4
Discussion
4.1 Rationale
Efferocytosis, the phagocytic removal of ACs, is critical for the maintenance of
homeostasis. Effective efferocytosis prevents autoimmunity and inflammation by
inhibiting the release of autoantigens and inflammatory intracellular contents, as well as
promotes the release of anti-inflammatory cytokines such as IL-10 and TGF-ß 27.
Moreover, following efferocytosis the degraded AC material is trafficked to the
recycling endosome, and thus, in addition to reducing the risk of autoimmunity,
efferocytosis may also aid in the recovery of nutrients from the AC 25,26. TAM family
receptors play a crucial role in efferocytosis, with MERTK representing the most
important TAM family member for maintaining homeostasis. Despite MERTK’s
significant clinical importance, it’s downstream signaling is poorly elucidated. Thus,
based on the literature and preliminary data from our lab, we set out to investigate the
downstream signaling pathway of MERTK.
Based on the dependence of MERTK on integrins for the engulfment of ACs and
MERTK induced activation of PI3K 52,53, we hypothesized that MERTK activates β2
integrins in order to mediate engulfment of ACs via a non-canonical phagocytic
signaling pathway. I established two objectives to address this hypothesis. My first
objective was to identify the proteins associated with MERTK and establish their role in
the MERTK mediated efferocytic signaling pathway. The second was to determine the
role of these signaling pathways in the MERTK-dependent regulation of integrin
affinity.

4.2 MERTK Signaling Pathway
While multiple signaling molecules were reported to be activated by MERTK, only the
activation of the PI3K pathway has been previously demonstrated, with this activation

72

occurring through the same canonical pathway as PI3K activation downstream of
phagocytic Fcγ receptors166. What other signaling molecules are activated by MERTK,
and their role in efferocytosis, is yet to be confirmed.
For my first objective, based on the literature and mass spectrometry analysis of proteins
that co-immunoprecipitated with MERTK, I developed a hypothetical MERTK signaling
pathway (Figure 7). In this pathway, we identified proteins that are critical to canonical
phagocytosis such as PI3K and SFK, and also identified non-canonical proteins such as
ILK. Next, we targeted and blocked these proteins with pharmacological inhibitors to
evaluate their role in MERTK mediated efferocytosis. As expected, efferocytosis was
blocked by the PI3K inhibitors. Two PI3K inhibitors were used, with differing
specificities for the various sub-families of PI3K - with LY294002 inhibits only the
RTK-activated Class I (PIP3-generating) PI3K’s, while wortmannin blocks all three
classes of PI3K including those which produce PI(3)P and PI(3,4)P 2167,168. These data
indicate that class I PI3K activity is required for MERTK-mediated efferocytosis,
consistent with canonical phagocytic signaling. Similarly, efferocytosis was also
diminished in presence of the SFK, ILK, and FAK inhibitors. Interestingly, both SFK
and FAK are previously implicated to facilitate the cross-talk between MERTK and
integrin63,121,147,169. Surprisingly, Syk inhibitor did not have any effect on efferocytic
uptake, suggesting that the MERTK kinase domain may replace the role normally
played by Syk during phagocytosis. Taken together, these inhibitor data demonstrate
that MERTK utilizes canonical phagocytic signaling molecules as well as distinct set of
non canonical signaling molecules to mediate efferocytosis.

4.3 Role and Activation of Integrin
Integrins are major class of transmembrane receptors. They mediate numerous cellular
processes ranging from adhesion, migration, proliferation, survival, differentiation,
mechano-sensing, phagocytosis, and cytoskeletal organization through a unique
bidirectional signaling between the extracellular environment and the cytoplasm. Several
studies have proposed that MERTK cross-talks with integrins, with MERTK and
integrins engaging in a synergistic modulation of the actin cytoskeleton, thus driving
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efferocytosis 122–124,134. Unpublished data from our lab has demonstrated that, in
macrophages, MERTK requires integrins for its efferocytic function, specifically that
MERTK first recognizes the AC, with the integrin then mediating the engulfment of the
AC (Figure 4A). As a reminder, we believe that many of the pathways activated by
MERTK mediate the cross-talk between MERTK and integrins, resulting in activation of
the latter. In order to address this possibility, in my second objective I used FRET to
directly quantify the activation of integrin in response to MERTK signaling.
The involvement of PI3K in MERTK mediated efferocytosis is well characterised 62.
PIP3, the product of this pathway, is known to activate ILK via an intrinsic PIP 3 binding
PH domain. This allows for ILK to be selectively recruited to areas of active PI3K
signaling135. When membrane-recruited, ILK binds to the intracellular tail of the integrin
β subunit170, ILK associates with multiple other signaling molecules, creating a complex
that can drive integrins from a low- to intermediary-affinity state 171–173. Our data is
consistent with a model wherein MERTK-derived PI3K signaling recruits ILK to the
efferocytic cup, and the recruited ILK drives integrins from their inactive to ligandaccessible conformation. These integrins can then bind integrin-specific opsonins within
the efferocytic cup. The resulting outside-in signaling through the integrin then mediates
the engulfment of the AC.
What is less clear is the role of FAK. In our data, inhibition of FAK also prevented
MERTK-dependent efferocytosis. FAK is involved in the bidirectional signaling through
integrins, with SFK-induced activation of FAK is capable of driving the inside-out
signaling that transitions integrins from a low-affinity to high-affinity state, and with
ligand binding inducing FAK-dependent outside-in signaling and actin
reorganization43,62,121,133,174. Conceivably, either or both pathways may be involved in
MERTK-mediated efferocytosis. FAK inhibition blocked inside-out activation of
integrins, consistent with a role for FAK in the initial activation of the integrin.
However, it is unclear whether outside-in signaling generated when integrins bind to
ligands is also required for efferocytosis. Unfortunately, we were unable to explicitly test
the role of outside-in signaling. Indeed, doing so may not be possible as many of the
same signaling pathways as activated by MERTK (e.g. PI3K, SFK) are also part of
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outside-in signaling175–177. Importantly, our integrin activation assays were conducted in
the absence of integrin ligands – meaning that all observed changes in integrin
conformation were due to inside-out signaling initiated by MERTK.

4.4 Complete Model of MERTK Signaling
Efferocytosis is a highly coordinated process that is regulated by a number of signaling
pathways, with several signaling molecules implicated in MERTK mediated
efferocytosis. However, in most cases their role is yet to be established, and it is unclear
which pathways are used to drive the engulfment of apoptotic cells versus used to drive
other downstream processes such as the transcriptional regulation of anti-inflammatory
responses69–71,76,147,178. In this thesis I have identified multiple pathways downstream of
MERTK, identified those required for efferocytosis, and determined that MERTKdriven efferocytosis occurs through a combination of canonical phagocytic signaling and
non-canonical signaling via ILK and FAK that allow MERTK to engage integrins to
assist in the engulfment of apoptotic cells. These pathways are illustrated in Figure 21.
As discussed previously, binding of MERTK to its opsonin leads to autophosphorylation
of its tyrosine kinase domain93,138,179,180. Upon activation it provides binding site for
Grb2 which recruits p85 subunit of PI3K, followed by the p110 kinase subunit which
phosphorylates PI(4,5)P2 to form PIP372,73. PIP3, via PH domains specific to this lipid,
initiates the recruitment of a range of proteins to the plasma membrane, thus driving
downstream activation of substrates and drive efferocytosis 63,138,148,181. While we have
not explored this pathway in-depth, in phagocytosis PIP 3 recruits a complex of Vav-1,
Rex-1 and DOCK, which then act as a GEF to activate Rac1. Active Rac1, through its
effectors, induces the actin polymerization which drives phagocytic cup formation 24.
PIP3 also mediates the recruitment and activation of Akt. In phagocytosis, Akt signaling
is not required for particle engulfment, but in other cell types Akt signaling, via mTOR,
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Figure 21: Proposed Model of MERTK-Mediated Efferocytic Signaling. MERTK
signaling induces several signaling pathways, some of which drive efferocytosis (Green)
and some which drive other cellular events (Blue). Proteins that facilitate efferocytosis
that were identified in this thesis are indicated by darker shades of green, while proteins
mediating efferocytosis that were identified previously in the literature are indicated by
lighter green shading.

76

regulates cell metabolism182. This may be a critical role for this signaling pathway
during MERTK-mediated efferocytosis, as the processing of apoptotic cells places a
high metabolic burden on the efferocytes. Indeed, the ability to process AC-derived
products such as cholesterol is the rate-limiting step in efferocytosis 183. As mentioned
above, PIP3 also recruits ILK to the plasma membrane via a PIP3-sepcific PH domain.
This is likely the key step in the activation of integrins following MERTK binding to an
AC135,170.
MERTK autophosphorylation may also lead to the activation of SFK which induce the
phosphorylation and activation of FAK134,138. Following activation, FAK is recruited to
integrin, promoting the transition of integrins to the high-affinity state 43 and enhancing
the formation of p130cas/CrKII/Dock180 complex to activate the cytoskeletal
assemblages required to internalize the AC62,146. The role of p38 MAPK in MERTK
function is less clear, and has not been reported previously, but may mediate the
expression of transcription factors necessary for the regulation of inflammation
following efferocytosis. Likewise, the activation of ERK by MERTK is not well
characterized, but may play a role in engulfment of the AC or in mediating
transcriptional responses64,154,184,185. Activated MERTK might also drive actin
reorganization directly through PKA, although this pathway remains unexplored. Lastly,
anti-inflammatory signaling is induced via inhibiting inflammatory cytokine signaling
through the JAK/STAT pathway75,76, resulting in the expression of both antiinflammatory cytokines, and SOCS1 and SOCS3, which inhibit cytokine signaling
through this pathway75,76.

4.5 Clinical Implications
Efficient efferocytosis is critical in maintaining homeostasis, whereas failed
efferocytosis can result in autoimmunity and inflammation owing to the release of
inflammatory cytosolic components and autoantigen from uncleared ACs 3–8. In addition,
altered processing of efferocytosed materials may lead to inappropriate presentation of
self-antigens, thus allowing deficits in efferocytic signaling to also lead to
autoimmunity. MerTK, as an efferocytic receptor, plays a crucial role in modulating
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homeostasis by mediating the efficient engulfment of ACs. Multiple studies have
demonstrated that mutations in MERTK predispose to several inflammatory and
autoimmune diseases due to impaired efferocytosis4,84,186. My discovery of the MERTK
signaling pathway may provide some additional insights into how altered MERTK
signaling may impact human health, some of which are discussed below.
For the maintenance of retinal health, the outermost, highly damaged segments of the
photoreceptor rod cells need to be recycled. This occurs via the phagocytic retinal
pigment epithelium cells, which use MERTK to clear the retina of these debris 84,88–91. In
the RCS rat, inactivating mutations in MERTK prevents this clearance, producing an
accumulation of photodamaged outer segments, leading to blindness due to the
inflammation induced following secondary necrosis of these uncleared outer segments.
This same process occurs in patients bearing a number of different mutations in MERTK,
with these mutations driving the most acute form of retinitis pigmentosa wherein
patients experience more severe disease, compared to disease driven by other mutations,
demonstrating the predominant role of MERTK in the retina84,92–97. Several of the
pathways downstream of MERTK are also known to be important for retinal
homeostasis. For example, mutations that inhibit p38 MAPK signaling cause a retinitis
pigmentosa-like disease driven by incorrect regulation of the actin cytoskeleton of the
efferocytic cells in the eye187. While I did not see an effect of p38 MAPK in my
macrophage model, non-professional phagocytes, such as the RPE cells in the eye, may
require augmentation of MERTK signaling via p38 MAPK to drive actin reorganization.
PI3K signaling, such as that generated by MERTK, aids in the survival of retinal cone
and rod cells, with decreased PI3K signaling associated with accelerated retinal
dystrophy188. While it is unclear at this time whether these pathways are activated by
MERTK, or other signals in the eye, these data do show that the pathways I identified
downstream of MERTK are important mediators of retinal homeostasis.
Macrophages are the predominant efferocytic cell type in the heart 3,107. These cells
mediate efferocytosis through MERTK, which normally acts to prevent atherosclerosis
by removing cholesterol-laden foam cells before they accumulate into an atherosclerotic
plaque99,103,105. In humans, a number of mutations in MERTK and its opsonin Gas6 are
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responsible for earlier onset of atherosclerosis and accelerated disease progression 109,110.
In mice, MERTK deficiency results in the inefficient clearance of ACs, leading to
disease exacerbation in atherosclerotic mouse model65,189. Of interest, I identified
multiple Src-family kinases associated with MERTK, and inhibitors of these proteins
negatively impacted MERTK-mediated efferocytosis. Interestingly, mutations in the
Src-family kinase pathway are often associated with other aspects of accelerated
atherosclerosis. A P76S SNP in BCAR1 – a major substrate of SFK – is a known genetic
risk factor for atherosclerosis and promotes vascular thickening 190. This variant of
BCAR1 has a mutation in its proline-rich region, which is required for interactions with
active Src-family kinases. Similarly, inactivating mutations in PHACTR1 are also
associated with accelerated atherosclerosis191. PHACTR1 is an actin-binding
phosphatase which disrupts the signal between SFK and FAK, leading to altered integrin
activity. Lastly, SNPs in ODIN/ANKS1A are also known risk-factors for
atherosclerosis191. ODIN is a direct target of multiple SFKs, and which regulates the
sensitivity of cells to many growth factor and cytokines through regulating the
trafficking of proteins to the cell surface. While these pathways would be activated by
multiple macrophage receptors, the loss of MERTK signaling in the heart may lead to
decreased activation of these pathways, causing similar pro-atherogenic changes in cell
behaviors due to decreased signaling that phenocopies the impact of these inactivating
SNPs.
MERTK has been implicated to play a crucial role in the pathogenesis of autoimmune
disorders such as SLE, which is a chronic autoimmune disease involving nervous,
cardiac, renal and respiratory systems driven by anti-nuclear autoantibodies. Mouse
macrophages lacking the tyrosine kinase domain of MERTK spontaneously produce
higher amount of inflammatory cytokine such as TNF-α 192, and develop lupus-like
autoimmunity186. Impaired clearance of the AC is thought to promote the development
of SLE by enhancing the release of nuclear proteins, which are the major self antigens in
patients with SLE116. However, both transmembrane and soluble MERTK (cleaved
extracellular portion of MERTK) expression are upregulated in SLE patients, with this
expression positively corelating with type I interferon (IFN-I) activity. This
overexpression did not elicit negative feedback of immune response. This discrepancy
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might be due to elevated soluble MERTK acting as a decoy of transmembrane MERTK
and leading to impaired efferocytosis, or due to the rapid cleavage of newly synthesized
MERTK193. Moreover, MERTK mutations are strongly associated with the risk of
hematological disorders such as leucopenia and/or lymphopenia, especially among
Korean SLE patients194. Multiple SFKs are implicated in this pathogenicity, while Syk,
one of the downstream molecules of SFK, is a therapeutic target for SLE 195. It is obvious
that molecules targeted to interfere with signaling pathways mediated by MERTK may
be useful in controlling the disease activity in SLE.
Taken together, all of these studies demonstrated the importance of MERTK mediated
efferocytosis signaling for efficient clearance of ACs and highlight how altered
signaling downstream of MERTK may contribute to disease progression. Moreover,
many of the proteins identified in this thesis as key regulators of MERTK efferocytosis
are also involved in these diseases, indicating that these signaling molecules may be
potential therapeutic targets. Critically, these diseases share several common themes in
regard to MERTK function - failed efferocytosis and altered anti-inflammatory
signaling. Thus, MERTK-targeted therapies may be useful across a range of diseases
where limiting inflammatory or autoimmune responses may be beneficial. Better
understanding of the signaling pathway can give us insight into the defects in MERTK
signaling and therefore, our results may be relevant to the identification of specific
molecular targets and lead to novel strategies to prevent these diseases.

4.6 Summary and Future Aims
MERTK is expressed in various tissues, and MERTK mediated signaling plays an
essential role in preventing inflammation and autoimmunity in these tissues. Through
removing apoptotic cells, and inducing anti-inflammatory signaling, MERTK thereby
act as a regulator of homeostasis.
In this thesis I have identified that MERTK mediates efferocytosis through a novel
signaling pathway which overlaps significantly with canonical phagocytic signaling, but
which also utilizes a unique integrin-activating pathway dependent on ILK and FAK.
Integrin activation is downstream of MERTK signaling and appears to be required to
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exert the physical forces that mediate AC engulfment, and without the integrinactivating signals, AC binding but not internalization is observed. The activation of
these integrins is regulated by MERTK via ILK and FAK – pathways previously shown
to be critical to the regulation of integrin affinity and function. Combined, these data
provide a greater understanding of the membrane-proximal signaling of MERTK and
identify the signaling pathways through which integrins facilitate MERTK function.
This fills in a large hole in our understanding of MERTK and TAM receptor function
and will enable future studies into MERTK and other TAM receptors to more
specifically target signaling pathways specific to distinct MERTK/TAM functions (e.g.
integrin activation vs. anti-inflammatory signaling). Thus, these data will help to guide
future studies into the signaling and cellular processes through which TAM receptors
contribute to the maintenance of homeostasis and enhances our knowledge of the
signaling and regulation of the TAM receptors.
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